Learn about Nifedipine, a calcium channel blocker used to treat hypertension and angina. Discover dosage, side effects, and drug interactions.
Browse our catalog for available pharmaceutical products and competitive pricing.
Nifedipine is a potent calcium channel blocker belonging to the dihydropyridine class of antihypertensive medications. It is classified under ATC code C08, which encompasses calcium channel blockers used in cardiovascular medicine. Nifedipine was first synthesized in 1972 and has since become one of the most widely prescribed medications for managing hypertension and angina pectoris worldwide.
This pharmaceutical compound works by inhibiting the influx of calcium ions into vascular smooth muscle cells and cardiac myocytes, leading to vasodilation and reduced cardiac workload. Nifedipine is available in multiple formulations, including immediate-release tablets, sustained-release formulations, and extended-release preparations, allowing for flexible dosing schedules tailored to individual patient needs.
The drug is known for its rapid onset of action, particularly in immediate-release forms, making it valuable in acute hypertensive situations. Its cardiovascular benefits extend beyond simple blood pressure reduction, as it provides additional therapeutic advantages in managing various cardiac conditions and improving overall cardiovascular health.
Nifedipine exerts its therapeutic effects primarily through selective inhibition of voltage-dependent L-type calcium channels. By blocking these calcium channels, the medication prevents calcium-mediated contraction of vascular smooth muscle and cardiac tissue. This mechanism results in arterial vasodilation, decreased peripheral vascular resistance, and reduced afterload on the heart. The drug demonstrates particular affinity for vascular smooth muscle compared to cardiac myocardium at therapeutic doses, which helps minimize negative cardiac inotropic effects while maximizing blood pressure-lowering benefits.
Nifedipine is a versatile cardiovascular medication with established efficacy in multiple clinical conditions. Its primary use centers on blood pressure management and angina relief, though its applications extend to various other cardiovascular and non-cardiovascular conditions. Healthcare providers may select Nifedipine as monotherapy or in combination with other antihypertensive agents, depending on individual patient characteristics and comorbidities.
Nifedipine dosing is highly individualized and depends on the specific formulation, clinical indication, patient age, renal and hepatic function, and concurrent medications. Immediate-release formulations provide rapid onset but require more frequent dosing, while extended-release preparations offer once-daily or twice-daily convenience with steadier drug levels. Initial doses are typically conservative to minimize adverse effects, with gradual titration based on therapeutic response and tolerability.
| Indication | Typical Dose | Frequency | Route |
|---|---|---|---|
| Essential Hypertension (Extended-release) | 30-90 mg | Once daily | Oral |
| Angina Pectoris (Extended-release) | 30-90 mg | Once daily | Oral |
| Hypertensive Urgency (Immediate-release) | 10-20 mg | Every 20-30 minutes as needed | Oral or sublingual |
| Vasospastic Angina (Immediate-release) | 10-20 mg | Three times daily | Oral |
Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Extended-release tablets should be swallowed whole without crushing or chewing. Grapefruit juice may inhibit Nifedipine metabolism and should be avoided during treatment. Regular monitoring of blood pressure and heart rate is essential during dose titration.
Nifedipine undergoes extensive hepatic metabolism through the cytochrome P450 enzyme system, particularly CYP3A4, making it susceptible to numerous clinically significant drug interactions. Concurrent medications that inhibit or induce these enzymes can substantially alter Nifedipine plasma concentrations and therapeutic effects. Patient education regarding potential interactions and regular medication review are essential components of safe therapy.
Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Do not use this information to self-diagnose or self-treat any medical condition. Nifedipine requires proper medical supervision and regular monitoring.
Yes, Nifedipine has an excellent safety profile for long-term use when properly monitored. Extensive clinical trials have demonstrated its safety and efficacy over decades of continuous therapy. However, regular medical follow-up is essential to assess blood pressure control, monitor for adverse effects, and adjust dosing as needed. Long-term use is associated with excellent cardiovascular outcomes in hypertensive and anginal patients when combined with appropriate lifestyle modifications and adherence to therapy.
Extended-release Nifedipine formulations can be taken with or without food and should be swallowed whole without crushing, chewing, or splitting. However, immediate-release formulations may be affected by food intake. More importantly, grapefruit and grapefruit juice should be strictly avoided, as they significantly increase Nifedipine plasma concentrations. Some patients find taking the medication with a light meal helps minimize gastrointestinal side effects. Always follow your specific prescriber's instructions regarding meal timing.
If you miss a dose of Nifedipine, take it as soon as you remember, unless it is almost time for your next scheduled dose. Never double the dose to make up for a missed dose. If you are unsure about missed dose management, contact your healthcare provider or pharmacist. Consistent dosing is important for maintaining steady blood pressure control, so using pill organizers or phone reminders can help prevent missed doses. For extended-release formulations, maintaining a regular dosing schedule is particularly important.